Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More


Editas News

September 22, 2014
FierceBiotech names Editas Medicine as one of its Fierce 15 Biotech Companies of 2014 Read More

June 24, 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer Read More

May 14, 2014
2014 NEVY Awards: Editas Medicine Wins Hottest Healthcare Startup Read More

April 25, 2014
Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers Read More

April 15, 2014
Editas Medicine Co-Founder is awarded First Patent for Engineered CRISPR-Cas9 System   Read More

February 13, 2014
Editas Medicine Co-Founder Publishes Key CRISPR Complex Structure in Cell Read More

February 7, 2014
Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science Read More


October 30, 2014
Nature Biotechnology: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.   Read More

October 19, 2014
Nature Biotechnology: In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9.     Read More

October 9, 2014
Cell: CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling.        Read More

September 28, 2014
Nature: Programmable RNA recognition and cleavage by CRISPR/Cas9.   Read More

August 11, 2014
Nature Methods: Improved vectors and genome-wide libraries for CRISPR screening.     Read More

July 1, 2014
Bioinformatics: Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA).   Read More